Sinopharm Group (SHTDF) Stock Price, News & Analysis

Company Overview

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Key Stats

• Today's Range: $2.49 to $2.49
• 50-Day Range: $2.49 to $2.65
• 52-Week Range: $1.97 to $2.95
• Volume: 81 shs
• Average Volume: 3,326 shs
• Market Capitalization: N/A
• P/E Ratio: 2.49
• Dividend Yield: 10.44%
• Price Target: N/A
• Consensus Rating: N/A

Sinopharm Group Stock Analysis - MarketRank™

Sinopharm Group scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Sinopharm Group.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sinopharm Group is 2.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.71.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sinopharm Group is 2.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.69.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Sinopharm Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sinopharm Group has recently decreased by 47.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Sinopharm Group pays a meaningful dividend of 1.11%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Sinopharm Group does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Sinopharm Group is 26.05%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Sinopharm Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sinopharm Group has recently decreased by 47.38%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Sinopharm Group this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sinopharm Group insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 16.47% of the stock of Sinopharm Group is held by institutions.

SHTDF Stock Analysis - Frequently Asked Questions

How have SHTDF shares performed this year?

Sinopharm Group's stock was trading at $2.49 at the start of the year. Since then, SHTDF stock has increased by 0.0% and is now trading at $2.49.
View the best growth stocks for 2025 here.

How do I buy shares of Sinopharm Group?

Shares of SHTDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 1/30/2025
• Next Earnings (Estimated): 3/20/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Distribution
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:SHTDF
• CUSIP: N/A
• CIK: 1556605
• Web: ir.sinopharmgroup.com.cn
• Phone: 86-21-2305-2666
• Fax: N/A
• Employees: 115,959
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 2.49
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A